Additional Indications Below for Module 4 and 5 clinical trials at UC Cancer

1 research study open to eligible people

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
open to eligible people ages 18-130
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
at UCSF

Last updated: July 12, 2022